ClinicalTrials.gg
RecruitingNCT05479474Updated Jan 13, 2026

Platelet Rich Plasma Testis Treatment for Infertile Men

An interventional study of Platelet rich plasma in Male Infertility, Nonobstructive Azoospermia and Azoospermia, sponsored by Stanford University. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-13.

Primary conditionAzoospermiaRegistry: Infertility, MaleReclassifiedWhy we changed it
Registry
Infertility, Male — the first condition term the registry derived for this study.
ClinicalTrials.gg
Azoospermia
Why
  1. The study's listed conditions name Azoospermia, a narrower term within Infertility, Male.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Stanford University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Study summary

Investigate the effect of intratesticular injection of autologous platelet rich plasma (PRP) on sperm retrieval rates and IVF outcomes in infertile men who already underwent a negative sperm retrieval. Currently, there is no alternative treatment after failed TESE. Prior series suggest that intratesticular PRP injections may improve TESE outcomes. We hope to determine whether PRP is an effective treatment for this patient population.

02

Conditions studied

  • Male Infertility
  • Nonobstructive Azoospermia
  • Azoospermia

Browse trials for

03

In context

Azoospermia Reclassified

59 studies on the registry are indexed under Azoospermia; 17 are open to participants now.

This study's planned enrollment of 10 is below the median of 57 across 32 interventional studies indexed under Azoospermia.

Browse Azoospermia studies →

Lead sponsor

Stanford University is the lead sponsor of 2,168 studies on the registry; 431 are open to participants now.

Of its 267 completed or terminated interventional studies of FDA-regulated products, 207 (78%) have results posted.

Compared within Azoospermia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infertility, Male. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men over the age of 18 diagnosed with NOA and at least one failed TESE, negative mapping or negative

Exclusion criteria

Exclusion Criteria:

-

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Platelet rich plasma treatment arm

    After consent in obtained, the patient will undergo a blood draw (12 tsp) to prepare the PRP infusion. The use of a centrifuge and an Arteriocyte Magellan kit are necessary for the PRP preparation. After injection of local anesthesia, PRP will be injected into each testicle.

    Biological: Platelet rich plasma

Interventions

  • Patients will undergo a blood draw (12 tsp) to prepare the PRP infusion. The use of a centrifuge and an Arteriocyte Magellan kit are necessary for the PRP preparation. After injection of local anesthesia, PRP will be injected into each testicle. * On the third month after the testicular PRP procedure, a TESE will be performed * If the procedure is successful a new IVF cycle using the sperm procured from the procedure will be done.

06

What researchers measure

Primary outcomes

  1. sperm present

    A TESE procedure will be performed to determine if sperm are present

    Time frame: 3 months after PRP injection

07

Study locations

1 of 1 sites recruiting
  • Stanford Urology Clinic
    Stanford, California 94304, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Dec 2026, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2022
First posted
Jul 29, 2022
StartActual
Jan 18, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05479474
Responsible party
Michael Eisenberg (Principal Investigator, Stanford University) — Principal investigator
First posted
Jul 29, 2022
Start date
Jan 18, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 13, 2026

Study contacts

Satvir Basran
Contact
sbasran@stanford.edu
650-723-0948

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Platelet rich plasma

Start the discussion